The screening equipment for elderly dementia (cognitive impairment screening system) adopts a combination of graphic drawing parallel coordinate graph and radar graph to visualize and quantify EEG and behavioral control. Through real-time recording and point distribution calculation of the graphic drawing process, as well as variable scale singular value analysis and calculation of EEG physiological parameters in time-frequency domain, the diagnosis and early risk assessment of Alzheimer's disease are achieved!
Product Details
Product registration name: Early cognitive function screening device
ADDSElderly dementia screening equipment (cognitive impairment screening system)It is a domestically produced medical grade early screening device for cognitive impairment, which has obtained medical device registration certification. Its core is used for early screening, brain function assessment, and risk grading of Alzheimer's disease (senile dementia) and mild cognitive impairment. It is widely suitable for hospital neurology, geriatrics, physical examination centers, community health service centers, and other scenarios.
2、 Core technical principles
The equipment innovation adopts the three-dimensional fusion technology of "international standard scale+dynamic electroencephalogram (EEG) monitoring+AI intelligent analysis", breaking the limitations of traditional single scale screening and achieving precise combination of subjective behavior assessment and objective EEG physiological data.
Standard Scale Evaluation: The built-in MMSE (Mini Mental State Examination), MoCA (Montreal Cognitive Assessment), and ADL (Activities of Daily Living) core scales guide participants to complete six dimensional tasks including memory, language, attention, executive function, visual spatial ability, and orientation through touch based human-machine dialogue, and automatically record behavioral data throughout the process.
Dynamic EEG monitoring: Equipped with non-invasive high-precision EEG acquisition electrodes, it captures the dynamic changes of subjects' alpha waves, beta waves, and theta waves in real time, extracts 12 nonlinear feature quantities such as singular value decomposition matrix parameters, complexity, approximate entropy, wavelet entropy, etc., and accurately captures subtle EEG abnormalities in the early stage of cognitive impairment.
AI intelligent fusion analysis: Using the variable scale maximum correlation minimum redundancy algorithm, the subjective data of the scale is fused with the objective indicators of EEG to automatically generate visual reports such as parallel coordinate graphs and radar graphs, and quickly complete the entire process analysis.
3、 Core functions
Early precision screening: Targeting Alzheimer's disease and mild cognitive impairment (MCI) to achieve early identification and solve the pain points of traditional screening, such as insufficient sensitivity and easy missed diagnosis.
Multidimensional cognitive assessment: covering six core cognitive dimensions including memory, language, executive function, visual spatial ability, attention, and daily living ability, comprehensively quantifying the degree of cognitive impairment.
Objective detection of brain function: non-invasive collection of EEG signals, objectively reflecting the state of brain neural activity, avoiding the errors of traditional scales that rely on subjective judgment by doctors and are influenced by emotions.
Automatic generation of professional reports: One click output of structured screening reports, including four core modules: cognitive scoring, EEG feature analysis, risk level classification, and intervention recommendations, supporting data storage, traceability, and comparative analysis.
Suitable for multi scenario screening: catering to the precise diagnosis needs of tertiary hospitals and the general screening needs of large-scale populations in the community, with simple operation and no need for professional EEG knowledge. Grassroots medical staff can get started with simple training.
4、 Product advantages
Non invasive safety, high comfort: non-invasive throughout the entire process, highly accepted by the elderly, painless and uncomfortable.
Easy to operate, efficient and time-saving: touch based interactive interface, one click start, no need for complex preparation, quickly complete single person screening, suitable for large-scale screening scenarios.
Objective results with high accuracy: The scale and EEG data are verified in both directions, and AI intelligent analysis reduces human errors, providing reliable basis for early intervention.
Strong adaptability and controllable cost: low operating cost, no need for consumables, high cost-effectiveness for long-term use.
Compliant with guideline recognition: The technical solution meets the integrated diagnostic requirements of the "Chinese Alzheimer's Disease Dementia Diagnosis and Treatment Guidelines" and has been clinically applied in medical institutions in multiple provinces and cities in China, adapting to the closed-loop management needs of elderly cognitive health "screening intervention".
Primary healthcare: community health service centers, township health centers (elderly health management);
Elderly care institutions: nursing homes, health centers (cognitive health screening and graded nursing);
Public welfare screening: Elderly health public welfare activities, community elderly population screening.
6、 Clinical value
Alzheimer's disease has the characteristics of "insidious onset, irreversibility, and good early intervention effect". Clinically, it is believed that "it cannot be cured but can be effectively delayed", and early screening is the core prerequisite for achieving intervention. ADDS devices achieve early detection, diagnosis, and intervention of elderly dementia through precise, efficient, and non-invasive screening methods, helping to delay disease progression, reduce the burden of family and social care, and assist in building a comprehensive management system for elderly cognitive health.
